Listed by the USPTO as MOORE, SUSANNA
Tech Center 1600 • Art Units: 1624 1625 1626
This examiner grants 68% of resolved cases
MOORE, SUSANNA is assigned to Tech Center 1600 and Art Unit 1624. The profile covers 1271 resolved cases, with a 68.0% allowance rate, a 31.6% interview lift, and a median time to allowance of 1062 days. The listed companies are The Regents of the University of California, Globachem NV, and The Trustees of Columbia University in the City of New York. The listed firms are OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P., COOLEY LLP, and KLARQUIST SPARKMAN, LLP.
The substantial resolved-case volume supports portfolio-level review of prosecution patterns. The allowance rate is more than twice the interview lift, so the overall disposition measure is broader than the interview-associated measure. The 1062-day median provides a planning reference for applicants assessing expected prosecution duration. Counsel can use the listed institutions and firms to locate comparable matters and evaluate claim strategy, amendment practice, and interview timing. The figures should inform that review without replacing application-specific analysis of disclosure, prior art, and examiner positions.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18584298 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | Final Rejection | Genentech, Inc. |
| 18283395 | ALGOSTATIC AGENTS FOR PREVENTING TRANSITION FROM ACUTE TO CHRONIC PAIN | Non-Final OA | The Regents of the University of California |
| 17753902 | METHOD OF MAKING AND/OR ISOLATING ISOIDIDE, COMPRISING SELECTIVE ESTERIFICATION OF A MIXTURE OF DIANHYDROHEXITOL ISOMERS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17676211 | Compounds to Identify Beta-Lactamases, and Methods of Use Thereof | Final Rejection | The Regents of the University of California |
| 18680689 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | Final Rejection | Hoffmann-La Roche Inc. |
| 18663097 | FLUORINATED PHTHALOCYANINE COMPOUND, COLORING COMPOSITION, AND INKJET INK | Non-Final OA | FUJIFILM CORPORATION |
| 18871590 | CRYSTALLINE FORMS OF AN AKRIC3 DEPENDENT KARS INHIBITOR | Non-Final OA | Novartis AG |
| 18277765 | SMALL MOLECULE ALLOSTERIC MODULATORS OF CLASS B GPCR, THE PTHR, AND METHOD TO IDENTIFY THEM | Final Rejection | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18869346 | NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | Non-Final OA | The Johns Hopkins University |
| 18038579 | ENANTIOSELECTIVE ALKENYLATION OF ALDEHYDES | Final Rejection | AMGEN INC. |
| 17911388 | METHODS OF CONTROLLING OR PREVENTING INFESTATION OF PLANTS BY THE PHYTOPATHOGENIC MICROORGANISM CORYNESPORA CASSIICOLA, CERCOSPORA SOJINA AND/OR CERCOSPORA KIKUCHII | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18715147 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Final Rejection | Vanderbilt University |
| 18905925 | DEUTERATED DERIVATIVES OF RUXOLITINIB | Final Rejection | Sun Pharmaceutical Industries, Inc. |
| 17758492 | TARGETED STEROID COMPOUNDS | Non-Final OA | Purdue Research Foundation |
| 18276432 | Branched Linkers for Antibody-Drug Conjugates and Methods of Use Thereof | Non-Final OA | R.P. Scherer Technologies, LLC |
| 17912429 | COMPOSITIONS AND METHODS FOR TREATMENT OF PATHOLOGIC PAIN ASSOCIATED WITH MALIGNANT GROWTH DISORDER | Final Rejection | Duke University |
| 18292565 | RAS/RAF BINDING INHIBITOR COMPOUND | Non-Final OA | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY |
| 18014057 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Non-Final OA | REMIX THERAPEUTICS INC. |
| 17620630 | USE OF DISULFIRAM OR ITS DERIVATIVES FOR THE TREATMENT OF MITOCHONDRIAL DISEASES OR DYSFUNCTION | Final Rejection | Universite De Bordeaux |
| 18646264 | IBOGAINE AND NORIBOGAINE ANALOGS AND METHODS OF USE | Non-Final OA | Atai Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy68.0% of resolved applications examined by Susanna Moore were allowed (1,271 resolved cases), compared with 54.4% across Art Unit 1624 over the last five years.
This examiner's interview lift is +31.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Susanna Moore took 1,062 days on average from filing to allowance.
Susanna Moore examines applications in Art Unit 1624 in Tech Center 1600 (Biotechnology & Pharmaceuticals).